Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
JN.1.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.11.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JD.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.13.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.32.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.4.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.86.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.34NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JG.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HV.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.58NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KQ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.46NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.48NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.47.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.7.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.8.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GJ.1.2.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.33.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.4.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JJ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GK.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HN.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GJ.1.2.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.3.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.6.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FD.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DV.7.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DV.7.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCLNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCTNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.86.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDD.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GK.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HW.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HN.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GE.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used